Promega Designs New Luciferase Reporter Assay for Drug Screening

Penny Patterson
Promega Corporation
Manager, Marketing Communications
[email protected]

MADISON, Wis.–(BUSINESS WIRE)–Promega Corporation offers the new ONE-Glo™ Luciferase Assay Reagent, based on a completely novel luciferin analogue, that exhibits improved reproducibility with fewer false positives while generating an extended bright light signal.

The ONE-Glo Luciferase Assay Reagent is based on a novel luciferase substrate, developed by Promega scientists, that renders the reagent more tolerant to different sample and reaction components. ONE-Glo exhibits reduced influence from luciferase inhibitors thereby resulting in fewer false positive readings, especially critical in screening applications. The percentage of likely drug compounds can be pursued and better prioritized, further reducing screening bottlenecks.

The new reagent is also optimized for batch and continuous-process handling. The extended bright light output of ONE-Glo allows for high sensitivity, especially when extended incubation is required prior to reading results. Enhanced stability at room temperature and larger package sizes for screening experiments means scientists can focus more effort on running successful assays and less on reagent preparation.

Bioluminescence-based assays are increasingly being used in drug screening applications as demands for improved sensitivity and ease of use at ever greater levels of throughput increase. Promega continues to develop numerous bioluminescent assays that allow scientists to more easily study different biological activities and physiologically relevant cellular events. Bioluminescent tools developed at Promega are routinely used to profile small molecule compounds, and to study druggable targets such as GPCRs/nuclear receptors, proteases and kinases, as well as to assess cell viability and cytotoxicity.

ONE-Glo is immediately available through the Promega Early Access Program and available for sale the end of August.